Pro-metastatic functions of lipoproteins and extracellular vesicles in the acidic tumor microenvironment

Anna Bång-Rudenstam1 · Myriam Cerezo-Magaña1 · Mattias Belting1

Published online: 15 February 2019 © The Author(s) 2019

Abstract

Although the overall mortality in cancer is steadily decreasing, major groups of patients still respond poorly to available treatments. The key clinical challenge discussed here relates to the inherent capacity of cancer cells to metabolically adapt to hypoxic and acidic stress, resulting in treatment resistance and a pro-metastatic behavior. Hence, a detailed understanding of stress adaptive responses is critical for the design of more rational therapeutic strategies for cancer. We will focus on the emerging role of extracellular vesicles (EVs) and lipoprotein particles in cancer cell metabolic stress adaptation and how these pathways may constitute potential Achilles’ heels of the cancer cell machinery and alternative treatment targets of metastasis. In this context, common extracellular lipid uptake mechanisms, involving specific cell-surface receptors and endocytic pathways, may operate during remodeling of acidic atherosclerotic plaques as well as the tumor microenvironment. The role of endocytosis in regulating the cellular response to hypoxic and acidic stress through spatial coordination of receptor proteins may be exploited for therapeutic purposes. As a consequence, molecular mechanisms of endocytosis have attracted increasing attention as potential targets for tumor specific delivery of therapeutic substances, such as antibody–drug conjugates. The identification of internalizing surface proteins specific to the acidic tumor niche remains an unmet need of high clinical relevance. Among the currently explored, acidosis-related, internalizing target proteins, we will focus on the cell-surface proteoglycan carbonic anhydrase 9.

Keywords Cancer · Acidosis · Metastasis · Proteoglycans · EVs · Lipid metabolism

1 The acidic tumor microenvironment

Cancer develops in a complex milieu, also known as the tumor microenvironment (TME), where the malignant cells and its stroma, including endothelial cells, pericytes, fibroblasts, immune cells, and the extracellular matrix (ECM), coexist during tumor evolution (for review, see [1]). Oncogenic events initially drive malignant development. However, stress factors such as hypoxia and acidosis have a key role early on in tumor development that, together with genetic factors, further fosters the selection of pro-metastatic subpopulations of highly heterogeneous tumors (Fig. 1). We will give a brief overview of the local metabolic functions of tumor hypoxia and extracellular acidosis and their role in ECM remodeling. A more detailed discussion will then focus on different aspects of tumor acidosis and lipid metabolism, and acidosis as a modulator of several functional aspects of malignant features involving EVs and lipoproteins, both locally in the primary tumor and at more distant locations, including the pre-metastatic niche (PMN). Finally, we will discuss potential therapeutic implications connected with tumor adaptive responses to hypoxia and acidosis.

2 Structural remodeling of the acidic tumor niche drives metastasis

As a key component of the TME, the ECM comprises the three-dimensional network of extracellular molecules that provide structural and biochemical support for surrounding cells. During tumor evolution, both the content and the organization of the ECM are altered in close concert with the hypoxic and acidic tumor landscape [2–4], ultimately contributing to metastasis and disease progression (Fig. 2). The major components of the ECM include fibrous proteins such as collagens, elastin, fibronectin and laminin, and proteoglycans (PGs) [5]. The interplay between the ECM and the acidic TME is considered important in several aspects of metastasis; detachment
from the surrounding stroma, migration, and local invasion are some of the first steps a cancer cell must take to further disseminate to and finally thrive in a new tissue compartment. Many of the early metastatic events are supported by the “imbalance” in intracellular and local extracellular pH, a phenomenon referred to as the “reversed pH gradient.” This is characterized by a low extracellular pH (pHe) concomitantly with a slightly alkaline intracellular pH (pHi) (further reviewed in [3, 6]). An acidic extracellular pH stimulates processes important for cancer cell migration by the induction and activation of ECM digestive enzymes, including matrix metalloproteinases (MMPs) and cathepsins, i.e., acidosis-activated proteases. Under physiological conditions, MMPs function to control homeostasis of connective tissue in various organs [7]. In the acidic TME, however, the abundance and activity of these enzymes are highly induced to serve as key players in the remodeling of the ECM [8–11]. The degradation of the ECM is further accelerated by the activity of heparanase, i.e., an acidosis-activated endoglycosidase that degrades heparan sulfate (HS) glycosaminoglycans (GAGs) [12]. During matrix degradation, sequestered pro-tumorigenic factors, including growth factors, cytokines, and chemokines, are liberated that further enhance pro-invasive signaling of tumor cells [13, 14]. Notably, non-classical signaling molecules of the TME, including EVs and lipoproteins, are known to interact with PGs in the ECM. As a consequence, low pH conditions, favoring increased protease and heparanase activity in the TME, should also influence the availability of these nanoparticle structures with potential signaling and metabolic functions, locally as well as systemically (further discussed below).

3 Metabolic rewiring is associated with acidification of the tumor niche

Changes in cell metabolism are a hallmark of cancer [15] as tumor cells rely on their ability to rewire their anabolic and catabolic pathways in order to obtain both energy in the form of ATP and complex molecules like lipids for processes such as cell division (Fig. 3). A well-established metabolic feature of tumor cells is their preferential use of glycolysis over oxidative phosphorylation (OXPHOS) for ATP production. In the core of solid tumors, hypoxic cells rely on glycolysis because of their inability to have a functional OXPHOS due to oxygen unavailability. Even under normal oxygen conditions, cancer cells rewire their metabolism to “aerobic glycolysis” (Warburg effect). Some tumor types, however, still rely on mitochondrial respiration as a major source of ATP [16, 17]. The increased glucose metabolism in solid tumors for energy production translates into lactate production from pyruvate fermentation and constitutes the driving force of extracellular acidification. CO₂ released by cancer cells undergoing mitochondrial
Respiration further contributes to acidosis by its hydration into $\text{HCO}_3^- + \text{H}^+$, catalyzed by carbonic anhydrases [18].

The immense lactate production that occurs in glycolytic, hypoxic areas has been studied as a nutrient source in solid tumors. Lactate can be taken up by cancer cells through monocarboxylate transporters (MCTs) and be utilized for energy production through oxidative metabolism. Interestingly, a symbiotic relation has been postulated between glycolytic, lactate-producing cancer cells, and cells relying on oxidative metabolism in areas where $\text{O}_2$ is available. “Oxidative cells” may internalize lactate through MCT1 in favor of glucose and utilize it for mitochondrial oxidation. In this way, glucose availability is increased for the glycolytic, hypoxic cells. Targeting lactate metabolism in the oxygenated areas by MCT1 blockade increases glucose in these cells and indirectly causes hypoxic cell death due to decreased remnant glucose availability [19].

In the acidic TME, increased free fatty acid uptake in the form of palmitate was reported, and acidosis-adapted cells use palmitate as a metabolic substrate for mitochondrial respiration [20]. In the same study, Corbet et al. suggest that fatty acid oxidation (FAO) occurs concomitantly with FA synthesis in acidosis-adapted cells, which in healthy tissues are usually mutually exclusive. Changes in the protein acetylome of acidosis-adapted cells may downregulate acetyl CoA carboxylase (ACC2) that would normally prevent FAO of newly synthesized lipids [20]. In this scenario, FAO is the major source of acetyl CoA (AcCoA) for the mitochondria, which in the presence of oxygen is metabolized by OXPHOS. Moreover, increased glutamine uptake, together with a positive regulation of glutamine metabolism enzymes, was suggested in acidosis-adapted cells, and this shift to reductive glutamine metabolism was connected with a change in histone acetylation of hypoxia-inducible factor (HIF)-responsive genes [21]. Notably, the increased AcCoA production by reductive glutamine metabolism from $\alpha$-ketoglutarate constitutes the substrate for de novo lipogenesis and fuels this pathway under acidic conditions, as it has been shown previously in hypoxic stress [22]. Acidosis-adapted cells are shown in this context to be
“mitochondrially active” through TCA cycle utilization of AcCoA from FAO and glutamine reductive metabolism. Under these conditions, mitochondria-inhibiting agents, like metformin, would be interesting candidates as repurposing drugs against the well-oxygenated acidic tumor niche, however, with less activity in the lactate-driven acidic tumor core [16].

4 Lipids as fuel for metastasis: role of tumor acidosis

Building on the findings on glucose metabolism, lipid metabolism has gained increasing interest in cancer due to numerous studies that link changes in tumor cell lipid availability to the metastatic potential of malignant cells. Lipids can accumulate in the cytoplasmic compartment in organelles referred to as “lipid droplets” (LDs), composed of neutral lipids and cholesteryl esters, and surrounded by perilipins and other specific coat proteins. Aberrant LD accumulation has been shown in a variety of cancer types [23–26]. Importantly, LD accumulation is affected by environmental stress like acidosis and hypoxia [27, 28] as well as chemoresistance [26] and can be mediated both by de novo lipogenesis and extracellular lipid uptake [27, 29]. Sterol regulatory element-binding proteins (SREBPs) are master regulators of a lipogenic program that controls cholesterol homeostasis and regulates the expression of target genes for lipid uptake (e.g., LDLR) and cholesterol biosynthesis (HMGCoA synthase and reductase).

Extracellular acidosis has been suggested to indirectly activate the SREBP pathway through SREBP-2 nuclear translocation. Despite other studies describing an increased pHi concomitant with extracellular acidosis [21, 30], studies of acidosis-adapted cancer cells from different tumor origins suggest that a decrease in pHi results in SREBP-2 related gene expression targeting different lipid pathways constitute interesting therapeutics targeted at metastatic cells (shown in red). Extracellular acidosis-mediated effects are represented with yellow boxes. α-KG alpha-ketoglutarate, ACC2 acetyl-CoA carboxylase, ACAT Acyl-CoA cholesteryl acyltransferase, AcCoA Acetyl CoA, CA9 carbonic anhydrase 9, CE cholesteryl ester, EV extracellular vesicle, FA fatty acid, FAO fatty acid oxidation, FAS fatty acid synthase, Glu glucose, GLUT1 glucose transporter 1, HMGCR HMGCoA reductase, HMGCS HMGCoA synthase, LDLR low-density lipoprotein receptor, LDs lipid droplets, LP lipoprotein, MCD methyl-β-cyclodextrin, MCT monocarboxylate transporter, OXPHOS oxidative phosphorylation, pH intracellular pH, Pyr pyruvate, SREBP sterol regulatory element-binding protein.
activation. However, the mechanism linking changes in pH and SREBP activation are still elusive [31]. Other studies revealed that increased expression of lysophosphatidylcholine acyltransferase 2 (LPCAT2), i.e., a key enzyme in phosphati-
dylycholine synthesis, correlated with an increased LD content and was shown to co-localize with LDs in colorectal cancer. Interestingly, the LD phenotype may promote chemoresistance by a mechanism involving ER stress inhibi-
tion, and inhibition of LD formation reversed the resistance phenotype [26]. LD-loaded cancer cells have shown increased metastatic potential in an experimental lung cancer model [27], and excessive LD accumulation was found in patient prostate cancer metastases [32]. Moreover, inhibition of cho-
lesterol esterification significantly suppressed the develop-
ment of metastatic lesions in experimental prostate cancer models, possibly through downregulation of the Wnt/β-
catenin pathway. PTEN is an established regulator of the
SREBP lipogenic pathway and is also commonly deleted in
prostate cancer [23]. In a model of metastatic prostate cancer,
the common co-deletion of PML and PTEN was suggested to
 drive metastatic potential through SREBP program activation.
The potential of SREBP as a therapeutic target was suggested
from treatment studies with fatostatin, which inhibits SREBP-
dependent de novo lipogenesis. SREBP inhibition resulted in
reduced prostate cancer cell growth and metastasis [23]. In
another study on metastatic pancreatic cancer [29], the ab-
rant cholesteryl ester accumulation in LDs was targeted with
avasimibe, which prevents free cholesterol esterification by
inhibiting acyl-CoA cholesterol acyltransferase-1 (ACAT-1).
Migration and invasion of pancreatic cancer cells were signifi-
cantly reduced by avasimibe, and metastatic dissemination to
the lymph nodes and liver was significantly reduced. This was
explained by free cholesterol accumulation and elevated ER
stress, further leading to apoptosis [29, 33]. ACAT-1 inhibition
has also shown promising results in a glioma model, as
free cholesterol accumulation after avasimibe treatment result-
ed in increased tumor cell death and prolonged animal sur-
av [34]. In contrast, studies with triple negative breast cancer
cells showed that LD consumption through FAO and CUB-
domain containing protein 1 (CDCP1) resulted in decreased
lipid accumulation and increased metastatic potential [35].
Although the exact role of LD consumption in the metastatic
process remains to be elucidated, LDs may serve as a substrate
reservoir of signaling lipid metabolites. As extensively de-
scribed [36], signaling lipids like eicosanoids, including
prostanoids and leukotrienes, have been linked to different
steps of metastasis development [36]. The increased abun-
dance of lipid substrates for their synthesis may increase their
potential as signaling entities in tumor development. Further
studies will be required to unravel how acquisition vs. con-
sumption of LDs in the acidic TME may be involved in pro-
moting the metastatic potential and how this differ depending
on tumor type.

The above studies mostly concern the role of endogenous
lipid metabolism. However, several studies point at the role of
exogenous lipid sources in metastasis. CD36, i.e., a hypoxia
induced scavenger receptor for extracellular lipids [37–39],
takes part in fatty acid and cholesterol uptake as well as in
signaling transduction of FA metabolism. In a study by
Pascual et al., slow cycling cells, with the greatest tumor ini-
tiating potential, overexpressed a repertoire of lipid metabo-
lism genes, including CD36. CD36 targeting with neutralizing
antibodies resulted in metastasis remission [40]. These effects
could be attributed to the lipotoxicity observed around LD-
laden cells in the metastatic niche. It was hypothesized that
CD36 is necessary for the initial steps of metastasis and that
CD36 blockade leads to LD accumulation and lipotoxicity.
Ladanyi et al. [41] reported that resident adipocytes of the
peritoneal cavity induced CD36 expression in ovarian cancer
cells, which associated with increased fatty acid uptake and
accumulation. Accordingly, silencing of CD36 resulted in im-
paired invasion, migration, and colony forming capacity [41].
Other studies have implicated a role for fatty acid binding
protein 4 (FABP4), i.e., another hypoxia-induced lipid trans-
port protein [42], in ovarian cancer metastasis. Overexpression of FABP4 in metastatic cells allowed efficient
internalization of fatty acids from adipocytes of the metastatic
niche, which was associated with enhanced cell growth [43].

5 Proteoglycans are major binding partners
of pH-sensitive ligands

PGs are present in virtually all mammalian tissue compart-
ments and constitute a large family of proteins characterized
by the covalent conjugation of one or several sulfated GAG
 polysaccharide chains. GAGs are composed of repeating di-
saccharide units of amino sugar (GlcnAc in heparan sulfate or
GalNAc in chondroitin sulfate) linked to uronic acid (GlcA or
IdoA). Sulfate groups are attached at discrete positions along
the GAG polysaccharide chain that together with carboxyl
groups yield a highly polyanionic structure prone to interac-
tions with sequences or patches of basic amino acids present
in a wide variety of protein ligands [44]. Being present intra-
cellulary, at the cell membrane and in the ECM, PGs partici-
pate in finely tuned electrostatic interactions. In cancer, the
conformations of these structures may be highly modulated,
altering structural as well as functional properties involved in
tumor development and progression [14, 45, 46]. Although it
is unlikely that the negative charge of the sulfate and carboxyl
groups (pKa < 2.0 and 3.0–4.4, respectively [47]) of PGs
would be affected by pH conditions of the TME (which in
more extreme cases may reach below pH 6 [48]), one could
still argue that the negatively charged GAG chains may influ-
ence the local distribution of free protons in the TME [49].
Thus, by reducing the diffusion capacity of positively charged
ions in the ECM, PGs could contribute to the extracellular acidification in their direct vicinity [50]. More importantly, increased protonation of histidine residues of protein ligands of the acidic TME would directly favor PG binding with consequences for their diffusion capacity in the ECM and internalization through PG-mediated endocytosis. We will next introduce PG-binding lipid particles that emerge as novel key players in TME remodeling and metastasis.

6 EVs and lipoproteins—PG binding nutrients and signalosomes of the TME

EVs are phospholipid-bilayer particles produced and found in most cells and tissues (see also Logozzi et al., this volume). These nanoparticles have a well-established role in intercellular communication, carrying nucleic acids, proteins, and lipids to neighboring as well as distant cells, thereby influencing a multitude of biological processes in both normal physiology and different pathological settings. EVs are usually classified according to their biogenesis, size, and method of release, where exosomes (30–150 nm in diameter) are, by definition, generated intracellularly within multivesicular bodies and are to be distinguished from microvesicles (MVs) (generally 100–1000 nm in diameter), which are shed from the plasma membrane, and from apoptotic bodies released from dying cells. However, the exact distinction between exosomes and MVs is still incomplete, partly due to inconsistent methods of purification, as well as incomplete understanding of their biogenesis, and the two terms are sometimes used interchangeably [51]. Here, we will use the common term EVs for both particles, unless otherwise stated.

The main classes of lipoproteins, i.e., HDL, LDL, VLDL, and chylomicrons, are in contrast to EVs surrounded by a single phospholipid membrane. These particles are classically regarded as carriers of lipids to peripheral tissues. LDL as well as other lipoproteins have been shown to interact with PGs, more specifically cell-surface heparan sulfate proteoglycans (HSPGs), for further clearance through endocytosis. Although the precise contribution of HSPGs in the uptake of lipoproteins is still under investigation, it is known that HSPGs are required for efficient lipoprotein internalization, either as independent receptors or in concert with classical cell receptors, e.g., LDLR, LPR1 VLDLR, SRB1, and CD36 [52–54]. Notably, EVs and lipoproteins, mainly LDL, have several similar features (for review, see ref. [55]); apart from similarities in size and density, increasing evidence shows that these endogenous nanoparticles play key roles in cancer cell adaptation to acidosis and hypoxia (see below). Consistent with this idea, we and others have found that cancer cell-derived EVs, more specifically exosomes, express HS-binding proteins [56], bind to heparin (a highly sulfated HSPG mimic), and are dependent on HSPGs for their efficient uptake [57]. From previous studies, a central role of PGs, more specifically HSPGs, as key players has emerged not only in the direct interaction but also in facilitating internalization and intracellular trafficking of endogenous nanoparticles of the TME [58–60]. How alterations in the structure and distribution of PGs in the acidic tumor niche regulate these functions is an interesting area for future studies.

7 What can we learn from atherosclerosis?

Although the detailed uptake mechanisms as well as the general impact of extracellular proton concentration on EV-to-cell and LDL-to-cell functions remain to be elucidated, some clues may be offered from another pathological process distinguished by anaerobic metabolism and acidosis: the atherosclerotic plaque. Malignant tumors and atherosclerotic lesions are different in many aspects, but there are some striking analogies between their pathological evolutionary trajectories [61, 62]. In addition to a hypoxic/acidic microenvironment, chronic inflammation and intracellular LD accumulation [63, 64] are common features. In atherosclerosis, the importance of lipid abundance in disease initiation and progression, mainly involving LDL, is well established, and EVs have attracted increasing interest as potential players in disease progression [65]. Several studies of atherosclerosis have shown that the affinity of LDL for PGs is quite low at neutral pH and is significantly enhanced with increasing extracellular acidity [66, 67]. Interestingly, LDL clearance by macrophages and smooth muscle cells, ultimately leading to foam cell formation, has been shown to be enhanced in both acidic and hypoxic atherosclerotic conditions, mainly through particle as well as HSPG receptor modifications [39, 68, 69]. In the tumor setting, we recently reported a role of HSPGs in the adaptive response of tumor cells to extracellular hypoxia and acidosis through increased internalization of lipoproteins, resulting in a LD storing phenotype that was associated with augmented spheroid formation and metastatic capacity [27]. Acidic extracellular pH could enhance the local availability of EVs/lipoproteins by increasing ligand retention as well as by directly affecting the PG-to-ligand electrostatic interaction, inducing binding, internalization, as well as affecting downstream signaling events. Although low pH is not considered to alter the PG net negative charge as such, enhanced proton accumulation in the vicinity of PGs (see above) could alter the net positive charge of surrounding ligands, a scenario that already has been discussed in the context of atherosclerosis [69]. Generally, sequences of positively charged arginine and lysine residues of ApoB-100 are known to be responsible for lipoprotein–PG interaction [70, 71]. However, protonation of histidine side chains (pKa of approximately 6.0) in ApoB-100 may, at least partly, explain the observed increase in lipoprotein–PG binding in the acidic atherosclerotic
microenvironment [69]. Notably, EVs have been shown to be enriched in specific lipoprotein ligands, including ApoE [72], known to bind HSPGs [73, 74], and net charge alterations of ApoE by acidic pH can be expected. Also, heat shock protein 90 (HSP90), i.e., another EV-enriched protein, was found to be enhanced in cancer cells cultured at low pH conditions with consequences for cancer stem cell malignancy [75]. Indeed, HSP90 has been shown to interact with cell-surface HSPGs [76], and HSP90-containing EVs were isolated from tumor cells [77], especially when derived from low-pH cell cultures [78]. This motivates further studies on the role of HSP90 in EV intercellular communication in the acidic tumor niche.

8 Increased release of tumor promoting EVs in the stressed TME

An increased release of EVs in response to hypoxia was reported [79–81], and more recently, the role of extracellular acidity in EV release has been explored. In several melanoma models, decreased extracellular pH was shown to induce EV secretion, and this was dependent on the metastatic capacity of donor cells [78, 82]. More recently, the influence of an acidic microenvironment on EV release was comprehensively evaluated, including several human tumor cell lines from colon, breast, and prostate cancers as well as melanoma and osteosarcoma. This study found an increase in EV release at acidic (pH 6.5) culture conditions as compared with physiological pH conditions, independently of tumor type [83]. Taken together, these studies point towards a general induction of EV secretion under acidic as well as hypoxic TME stress, which is in line with the idea that EV secretion is associated with the degree of tumor malignancy [84]. It has been speculated that enhanced EV secretion under acidic stress could work in favor of cell survival through elimination of toxic substances that otherwise would accumulate in stressed cells [85]. Apart from an induced EV secretion in acidic conditions, low pH was shown to increase EV protein and RNA stability [86], suggesting a more potent transfer of signaling molecules by acidosis-derived EVs.

9 Changes in the internalization mechanisms of acidic cancer cells: implications for EV uptake

As previously discussed, the importance of enhanced exploitation of exogenous nutrient sources, including lipoproteins and EVs, as well as other macromolecules in malignant tumors is gaining increased interest [87, 88]. Specifically, the role of macropinocytosis has been elaborated in cancer cells harboring oncogenic RAS mutations where extracellular protein is internalized through macropinocytosis and degraded to provide nutrient supply and cellular growth [89, 90]. The function of macropinocytosis as a feeding mechanism of extracellular macromolecules provides a new perspective in cancer cell metabolic reprogramming. Few studies have explored how TME features, including hypoxia and acidosis, may regulate the uptake of EVs, lipoproteins and other macromolecules that may occur via multiple processes including phagocytosis, macropinocytosis, receptor-mediated endocytosis, and direct membrane fusion [91, 92]. We have provided evidence that EVs mainly enter cells via lipid raft-mediated endocytosis through signaling activation of a MAPK-dependent route, and that this pathway is negatively regulated by caveolin-1 [93]. Further, we reported the importance of HSPGs as major internalizing receptors involved in EV uptake and, more importantly, in hypoxia/acidosis-induced LDL uptake, where signaling activation of the MAPK pathway modulated ligand endocytosis [27, 57]. Stress induced LDL uptake was further shown to be linked to an increased metastatic potential [27] and together with the findings on MAPK involvement in lipogenesis [23], these studies strengthen the role of MAPK in acid accumulation and metastatic potential of cancer cells.

So, how could the lipid raft-mediated endocytosis be modulated by acidosis? The levels of cholesterol in cancer cells are essential not only as building blocks for membrane formation during cell division and as substrates for signaling molecules but also as key constituents of lipid raft membrane domains [94]. Extracellular acidosis can modulate membrane lipid distribution as shown by an increased cholesterol abundance in the plasma membrane of acidosis-adapted glioblastoma cells, with potential consequences for lipid raft structure organization and cell signaling. Tumor cell survival was dramatically reduced after cholesterol depletion by methyl-β-cyclodextrin (MCD) treatment, suggesting an increased dependence on membrane cholesterol in acidosis-adapted cells [95]. Similarly, the integrity of lipid raft domains is important for epithelial-to-mesenchymal transition (EMT) regulation, and lipid raft disruption could lead to decreased invasiveness and chemoresistance in pancreatic tumor initiating cells [96]. Interestingly, in human glioblastoma tumor samples, an association was suggested between HMG-CoA-reductase (HMGR), the rate-limiting enzyme in cholesterol biosynthesis, and LAMP2, a suggested marker for acidosis [30], further supporting a dependency of acidic cancer cells on cholesterol levels and that this pathway is a relevant therapeutic target of stressed tumor niche [95].

The lipid membrane organization of EVs may be similarly affected by alterations in extracellular pH, ultimately influencing EV delivery to recipient cells in the acidic TME. Indeed, an increased EV uptake through membrane fusion has been suggested in acidic conditions [82]. Although EV-cell fusion generally is considered to be limited due to high rigidity of the EV membrane, altered EV lipid organization in low pH
conditions could affect EV-cell fusion potential. A study examining EV membrane fluidity by fluorescence anisotropy in different pH conditions found reduced membrane rigidity at lower pH conditions [97]. As fusion between membranes is facilitated by similar membrane fluidity, decreased pH could be suspected to promote EV delivery. Notably, treatment with the lipid metabolism inhibitor fSTATin was shown to decrease EV production [98], supporting an interplay between donor cell lipid metabolism and EV-dependent intercellular communication [99]. Further, macropinocytosis and phagocytosis are also regulated by extracellular pH conditions [100, 101]. In macrophages, an increased phosphatidylerine-dependent phagocytic capacity, dependent on acidosis-induced stabilin-1, was reported [102]. However, additional studies will be required to provide more firm conclusions regarding how these pathways are regulated in the acidic tumor niche with associated effects on EV transfer.

10 EVs promote hypoxia and acidosis-mediated tumor development and metastasis

Several studies have started to unravel potential functions of EVs in the acidic tumor niche, both locally and at distant sites in the PMN. The metabolite composition of EVs was shown to modulate the metabolism and serve as an energy source in recipient cells [103], e.g., hypoxia-derived EVs showed an enhanced triglyceride level [98]. Further, EVs from hypoxic adipocytes showed an increased content of lipogenic enzymes, and this metabolic phenotype was transferred to recipient cells [104]. It may be concluded that EVs have the potential to favor a lipid loaded phenotype not only through the transfer of their lipid content but also through pleiotropic effects imposed by the transfer of metabolic substrates and enzymes into recipient cells. Pannucci et al. suggested that conditioned media from acidic tumor cells can stimulate invasiveness of non-acidic melanoma cells and that a mixed population of acidic and non-acidic cells induced invasive and metastatic potential [105]. The specific role of acidosis-derived EVs in invasion and migration was further evaluated, proposing that exosomes secreted by acidic cells (including short-term and long-term, acidosis-adapted cancer cells) induced migration and invasion in recipient cells [78]. We have previously found that hypoxia-derived EVs mimic the hypoxic response in glioma tumor cells, resulting in enhanced in vivo tumor growth and remodeling of the stromal cell compartment [106]. Specifically, it was demonstrated that hypoxic tumor cells release pro-coagulant EVs, resulting in pro-tumorigenic effects in recipient stromal cells [107]. Moreover, the proteomic profile of EVs derived from tumor cells cultured in acidic pH (6.0) was altered, showing an increased expression of proteins involved in migration, invasion, metastasis, and survival [78]. Thus, it appears conceivable that acidosis-derived EVs, similarly to EVs from hypoxic conditions, take part in driving disease progression by conditioning of stromal cells as well as local remodeling of the ECM compartment in the primary tumor [108].

Importantly, EVs may also contribute to the generation of a suitable microenvironment at distant sites by conditioning and educating the PMN. The concept of PMN holds that cancer cells in the primary tumor secrete factors that can impact vascular integrity, ECM remodeling, and recruitment and reprogramming of bone marrow–derived cells (BMDCs), favoring future colonization by circulating cancer cells. The general role for EVs in PMN formation has been extensively reviewed elsewhere [109–112]. Here, it should be underlined that TME stress has in several studies been shown to regulate EV cargo composition [106, 113] as well as to promote vesicle shedding [79–81]. Erler and colleagues showed that hypoxia in the primary tumor can induce the secretion of lysyl oxidase (LOX) resulting in collagen cross-linking and ECM remodeling at distant sites that favor recruitment of BMDCs and eventual metastatic seeding [114]. Notably, we found LOX to be highly enriched in hypoxia-derived EVs [106] and others found LOX-like 2 (LOXL2) to be increased on the exterior of EVs derived from hypoxic endothelial cells [115]. Hence, hypoxia-derived EVs may function as an important delivery mechanism of LOX and LOXL2 as well as other actors involved in PMN formation. In addition, metabolic effects of tumor-derived EVs may modulate the metabolic status of cells at distant sites [103] as an additional mechanism whereby EVs take part in PMN conditioning.

11 Exploiting the endocytosis machinery for tumor drug delivery—finding the targets

We have discussed several examples of how metastatic cells of the acidic tumor niche fulfill their metabolic demands through induced uptake and utilization of extracellular ligands, such as EVs and lipoproteins. However, similar transport mechanisms may be harnessed for specific delivery of therapeutic substances to the stressed TME. Notably, several vesicle transport mechanisms are deregulated by stress factors of the TME [116]. As a consequence, membrane transport mechanisms have attracted increasing attention as portals of entry for tumor-specific delivery of therapeutic substances, such as antibody–drug conjugates (ADCs). The concept of ADC treatment is to repurpose an antibody as a toxin delivery vehicle to specifically kill tumor cells by intracellular release of the drug. ADCs targeting epidermal growth factor receptor 2 (HER-2) and CD20 have been approved in the treatment of breast cancer and lymphoma, and more than 40 ADCs are currently in clinical trials [117]. However, the identification of internalizing surface tumor antigens of the TME remains an
unmet need of high clinical relevance. We have developed a procedure for functional mapping of the cell-surface proteome and recently revealed that caveolin-1 acts as a global negative regulator of receptor internalization in hypoxic cells [118]. As an exception to the general downregulation of receptor internalization by hypoxia, carbonic anhydrase 9 (CA9), among others, was identified as a highly hypoxia specific, cell-surface receptor that could escape from the gate keeper function of caveolin-1. CA9 is highly induced at hypoxic and acidic conditions [119] and constitutes a major player in the regulation of tumor pH homeostasis [120, 121] by the reversible hydration of CO₂ into HCO₃⁻ + H⁺. Together with bicarbonate transport proteins, CA9 facilitates intracellular alkalinization with concomitant extracellular proton accumulation and acidification (see Bødkjer, this volume). In normal physiology, CA9 expression is restricted to a few organs including the upper gastrointestinal tract and gallbladder [122]. CA9 thus emerges as an attractive treatment target due to its specific expression in the stressed TME that further associates with worse patient prognosis [119]. Accordingly, several small molecule inhibitors and antibody-based drugs targeted at CA9 are currently explored in experimental models as well as in clinical trials [123] (see Pastorekova, this volume). We recently provided first evidence that CA9 exists in a GAG substituted version, i.e., as a part-time PG. Notably, the GAG-modified version of CA9 (PG-CA9) showed an impaired internalization in cancer cells due to translocation of PG-CA9 to caveolin-1 enriched membrane regions [124]. Based on these and other findings, it may be proposed that perturbation of CA9 glycosylation and/or caveolin-1 provides improved opportunities for enhanced targeting of the acidic tumor niche.

12 Conclusions

Deregulated lipid metabolism by the abnormal transfer not only of EVs and lipoproteins through cell-surface PGs but also of other extracellular nutrients and intracellular mechanisms, in the acidic tumor niche results in alteration of vital functions related to stress adaptation and enhanced metastatic potency. It is thus hypothesized that stressed-induced recruitment of lipoproteins and EVs represents a new mechanism of cancer cell adaptation. However, the details of EV/lipoprotein entry and cargo transfer into recipient cells, and how these events are regulated by acidosis, remain open and important questions. Thus, a major goal of future studies should be to gain a better understanding of how receptor complexes cooperate during uptake and intracellular sorting of extracellular lipoprotein particles and EVs. This opens a broad horizon of questions on the interplay between lipoprotein and EV particles in tumor biology: (1) Do they share/compete for similar uptake and signaling pathways in hypoxic/acidic tumor cells? (2) Do they follow similar intracellular sorting routes and metabolic pathways, e.g., as substrates for LD formation? and (3) What is the functional role of lipid loading at the levels of signaling activation, proliferation, migration, and survival in vitro as well as tumor cell metastasis in vivo? Moreover, further work is necessary to examine how metastatic cells mobilize and utilize lipids stored in LDs, i.e., are LDs consumed during periods of re-oxygenation/pH neutralization to resist cell death by oxidative stress? Could cancer cells support their survival through autophagy-dependent consumption of LDs during their journey in the well-oxygenated blood stream? Finally, how could the craving for extracellular lipids and other nutrient sources in the acidic TME be exploited therapeutically? Together, these avenues for future investigations should provide novel insights at the interface between metabolic disease (obesity) and cancer and establish the increased demand of extracellular lipid particles and lipid storage in stressed cancer cells as a new target for therapeutic intervention of metastasis.

Funding This study was funded by grants from the Swedish Cancer Fund CAN 2017/664; the Swedish Research Council VR-MH 2018-02562; the Swedish Childhood Cancer Foundation PR2015-0078; the Fru Berta Kamprad Foundations; the Skåne University Hospital donation funds; the Governmental funding of clinical research within the national health services, ALF; and a donation by Viveca Jeppsson.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

1. Quail, D. F., & Joyce, J. A. (2013). Microenvironmental regulation of tumor progression and metastasis. Nature Medicine, 19(5), 1423–1437. https://doi.org/10.1038/nm.3394.
2. Gilkes, D. M., Semenza, G. L., & Wirtz, D. (2014). Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nature Reviews. Cancer, 14(4), 430–439. https://doi.org/10.1038/nrc3726.
3. Webb, B. A., Chimenti, M., Jacobson, M. P., & Barber, D. L. (2011). Dysregulated pH: a perfect storm for cancer progression. Nature Reviews. Cancer, 11(6), 671–677. https://doi.org/10.1038/nrc3110.
4. Colpaert, C. G., Vermeulen, P. B., Fox, S. B., Harris, A. L., Dirix, L. Y., & van Marck, E. A. (2003). The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor
32. Lee, H. J., Li, J., Vickman, R. E., Li, J., Liu, R., Durkes, A. C., Elzey, B. D., Yue, S., Liu, X., Ratliff, T. L., & Cheng, J. X. (2018). Cholesterol esterification inhibition suppresses prostate cancer metastasis by impairing the Wnt/β-catenin pathway. Molecular Cancer Research, 16, 974–985. https://doi.org/10.1158/1541-7786.MCR-17-0665.

33. Lee, S. S. Y., Li, J., Tai, J. N., Ratliff, T. L., Park, K., & Cheng, J. X. (2015). Avasimibe encapsulated in human serum albumin blocks cholesterol esterification for selective cancer treatment. ACS Nano, 9, 2420–2432. https://doi.org/10.1021/nn504025a.

34. Bemlih, S., Poirier, M. D., & El Andaloussi, A. (2010). Acyl-coenzyme A: cholesterol acyltransferase inhibitor avasimibe affect survival and proliferation of glioma tumor cell lines. Cancer Biology & Therapy, 9, 1025–1032. https://doi.org/10.4161/cbt.9.12.11875.

35. Wright, H. J., Hou, J., Xu, B., Cortez, M., Potma, E. O., Tromberg, B. J., & Razorenov, S. O. V. (2017). CDCP1 drives triple-negative breast cancer metastasis through reduction of lipid-droplet abundance and stimulation of fatty acid oxidation. Proceedings of the National Academy of Sciences, 114, E6556–E6565. https://doi.org/10.1073/pnas.1701791114.

36. Luo, X., Zhao, X., Cheng, C., Li, N., Liu, Y., & Cao, Y. (2018). The implications of signaling lipids in cancer metastasis. Experimental & Molecular Medicine, 50, 127. https://doi.org/10.1038/s12276-018-0150-x.

37. Silverstein, R. L., & Febrario, M. (2009). CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Science Signaling, 2, 33. https://doi.org/10.1126/scisignal.272re3.

38. Chen, Y. P., Kuo, W. W., Baskaran, R., Day, C. H., Chen, R. J., Gutbrod, R., Hotamisligil, G. S., Yamada, S. D., Peter, M. E., Gwin, K., Gutbrod, R., Zillhardt, M. R., Romero, I. L., Carey, M. S., Mills, G. B., & Lengyel, E. (2011). Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nature Medicine, 17, 1498–1503. https://doi.org/10.1038/nm.2492.

39. Izzo, R. V., & Schafner, L. (2015). Proteoglycan form and function: a comprehensive nomenclature of proteoglycans. Matrix Biology, 42, 11–55. https://doi.org/10.1016/j.matbio.2015.02.003.

40. Izzo, R. V., & Sanderson, R. D. (2011). Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. Journal of Cellular and Molecular Medicine, 15, 1013–1031. https://doi.org/10.1111/j.1582-4934.2010.01236.x.

41. Nagarajan, A., Malvi, P., & Wajapeyee, N. (2018). Heparan sulfate and heparin sulfate proteoglycans in cancer initiation and progression. Front Endocrinol (Lausanne), 9, 483. https://doi.org/10.3389/fendo.2018.00483.

42. Chakrabarti, B., Park, J. W., & Stevens, E. S. (1980). Glycosaminoglycans: structure and interaction. Critical Reviews in Biochemistry and Molecular Biology, 8, 225–313. https://doi.org/10.3109/10409238009102572.

43. Vaupel, P., Kallinowski, F., & Okunieff, P. (1989). Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Research, 49, 6449–6465.

44. Maroudas, A., Weinberg, P. D., Parker, K. H., & Winlove, C. P. (1988). The distributions and diffusivities of small ions in chondroitin sulphate, hyaluronate and some proteoglycan solutions. Biophysical Chemistry, 32(2-3), 257–270.

45. Leake, D. S. (1997). Does an acidic pH explain why low density lipoprotein is oxidised in atherosclerotic lesions? Atherosclerosis, 129(2), 149–157.

46. Colombo, M., Raposo, G., & Théry, C. (2014). Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annual Review of Cell and Developmental Biology, 30, 255–289. https://doi.org/10.1146/annurev-cellbio-101512-122326.

47. Mahley, R. W., & Huang, Y. (2007). Atherogenic remnant lipoproteins: role for proteoglycans in trapping, transferring, and internalizing. The Journal of Clinical Investigation, 117, 1–5. https://doi.org/10.1172/JCI30889.

48. Stanford, K. I., Bishop, J. R., Foley, E. M., et al. (2009). Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice. The Journal of Clinical Investigation, 119, 3236–3245. https://doi.org/10.1172/JCI38251.

49. Wilsie, L. C., Gonzales, A. M., & Orlando, R. A. (2006). Syndecan-1 mediates internalization of apoE-VLDL through a low density lipoprotein receptor-related protein (LRP)-independent, non-clathrin-mediated pathway. Lipids in Health and Disease, 5, 23. https://doi.org/10.1186/1476-511X-5-23.

50. Menard, J. A., Cerezo-Magaña, M., & Belting, M. (2018). Functional role of extracellular vesicles and lipoproteins in the tumour microenvironment. Philos Trans R Soc B Biol Sci, 373, 20160480. https://doi.org/10.1098/rstb.2016.0480.

51. Harasztí, R. A., Didiot, M.-C., Leszyk, J., Shaffer, S. A., Rockwell, H. E., Gao, F., Narain, N. R., DiFilligia, M., Kiebisch, M. A., Atronin, N., & Khvorova, A. (2016). High-resolution proteomic and lipidomic analysis of exosomes and microvesicles from different cell sources. J Extracellular Vesicles, 5, 32570. https://doi.org/10.3402/jev.v5.32570.

52. Christianson, H. C., Svensson, K. J., van Kuppevelt, T. H., et al. (2013). Cancer cell exosomes depend on cell-surface heparan sulfate proteoglycans for their internalization and functional activity. Proceedings of the National Academy of Sciences, 110, 17380–17385. https://doi.org/10.1073/pnas.1304266110.

53. Christianson, H. C., & Belting, M. (2014). Heparan sulfate proteoglycan as a cell-surface endocytosis receptor. Matrix Biology, 35, 51–55. https://doi.org/10.1016/j.matbio.2013.10.004.

54. Wittrup, A., Zhang, S.-H., ten Dam, G. B., van Kuppevelt, T. H., Bengtson, P., Johannson, M., Welch, J., Mörgelin, M., & Belting, M. (2018).
M. (2009). ScFv antibody-induced translocation of cell-surface heparan sulfate proteoglycan to endocytic vesicles. The Journal of Biological Chemistry, 284, 32959–32967. https://doi.org/10.1074/jbc.M109.036129.

60. Belting, M. (2003). Heparan sulfate proteoglycan as a plasma membrane carrier. Trends in Biochemical Sciences, 28, 145–151. https://doi.org/10.1016/S0968-0004(03)00318-8.

61. Tapia-Vieyra, J. V., Delgado-Coello, B., & Mas-Oliva, J. (2017). Atherosclerosis and cancer: a resemblance with far-reaching implications. Archives of Medical Research, 48, 12–26. https://doi.org/10.1016/j.arcmed.2017.03.005.

62. Yurdagul, A., Finney, A. C., Woolard, M. D., & Orr, A. W. (2016). The arterial microenvironment: the where and why of atherosclerosis. The Biochemical Journal, 473, 1281–1295. https://doi.org/10.1042/B12105844.

63. Shyu, P., Wong, X. F. A., Crasta, K., & Thibault, G. (2018). Dropping in on lipid droplets: insights into cellular stress and cancer. Bioscience Reports, 38, BSR20180764.

64. Christopher Glass AK, Witztum JL (2001) Atherosclerosis: the road ahead review.

65. Su, S.-A., Xie, Y., Fu, Z., Wang, Y., Wang, J. A., & Xiang, M. (2021). Enhanced extracellular lipid accumulation in acidic environments. Current Opinion in Lipidology, 17, 534–540. https://doi.org/10.1097/01.mol.0000425259.63505.c2.

66. Wada, Y., Sugiyama, A., Yamamoto, T., Naito, M., Noguchi, N., Yokoyama, S., Tsujita, M., Kawabe, Y., Kobayashi, M., Izumi, A., Kohro, T., Tanaka, T., Taniguchi, H., Koyama, H., Hirano, K. I., Yamashita, S., Matsuzawa, Y., Niki, E., Hamakubo, T., & Kodama, T. (2002). Lipid accumulation in smooth muscle cells under LDL loading is independent of LDL receptor pathway and enhanced by hypoxic conditions. Arteriosclerosis, Thrombosis, and Vascular Biology, 22, 1712–1719. https://doi.org/10.1161/01.ATV.0000033834.57375.9B.

67. Örni, K., Rajamäki, K., Nguyen, S. D., Lähdesmäki, K., Pihlari, R., Lee-Rueckert, M., & Kovanen, P. T. (2015). Acidification of the intimal fluid: the perfect storm for atherogenesis. Journal of Lipid Research, 56, 203–214. https://doi.org/10.1194/jlr.R050525.

68. Camejo, G., Olofsson, S. O., Lopez, F., et al. (2017). Identification of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding. The Journal of Clinical Investigation, 101, 2658–2664. https://doi.org/10.1172/JCI2265.

69. Keerthikumar, S., Chisanga, D., Ariraratne, D., al Saffar, H., Anand, S., Zhao, K., Samuel, M., Pathan, M., Jois, M., Chilamkurthi, N., Gangoda, L., & Mathivanan, S. (2016). ExoCarta: a web-based compendium of Exosomal cargo. Journal of Molecular Biology, 428, 688–692. https://doi.org/10.1016/j.jmb.2015.09.019.

70. Libeu, C. P., Lund-Katz, S., Phillips, M. C., Wehrli, S., Hernáiz, M. J., Capila, I., Linhardt, R. J., Raffat, R. L., Newhouse, Y. M., Zhou, F., & Weisgraber, K. H. (2001). New insights into the heparan sulfate proteoglycan-binding activity of apolipoprotein E. The Journal of Biological Chemistry, 276, 39138–39144. https://doi.org/10.1074/jbc.M104746200.

71. Saito, H., Dhanasekaran, P., Nguyen, D., Baldwin, F., Weisgraber, K. H., Wehrli, S., Phillips, M. C., & Lund-Katz, S. (2003). Characterization of the heparin binding sites in human apolipoprotein E. The Journal of Biological Chemistry, 278, 14782–14787. https://doi.org/10.1074/jbc.M213207200.

72. Filatova, A., Seidel, S., Bögürçü, N., Gräf, S., Garavalov, B. K., & Acker, T. (2016). Acidosis acts through HSP90 in a PHD/VHL-independent manner to promote HIF function and stem cell maintenance in glioma. Cancer Research, 76, 5845–5856. https://doi.org/10.1158/0008-5472.CAN-15-2630.

73. Snigireva, A. V., Vrublevskaya, V. V., Afanasyev, V. N., & Morenkov, O. S. (2015). Cell surface heparan sulfate proteoglycans are involved in the binding of Hsp90α and Hsp90β to the cell plasma membrane. Cell Adhesion & Migration, 9, 460–468. https://doi.org/10.1080/19336918.2015.1103421.

74. McCreary, J., Sims, J. D., Chan, D., & Jay, D. G. (2010). Secretion of extracellular hsp90α via exosomes increases cancer cell motility: a role for plasminogen activation. BMC Cancer, 10, 294. https://doi.org/10.1186/1471-2407-10-294.

75. Boussadia, Z., Lambert, J., Mettei, F., Pizzi, E., Puglisi, R., Zanetti, C., Pasquini, L., Fratini, F., Fantozzi, L., Felicetti, F., Vecchi, K., Raggi, C., Sanchez, M., D’Atri, S., Carè, A., Sargiacomo, M., & Parolini, I. (2018). Acidic microenvironment plays a key role in human melanoma progression through a sustained exosome mediated transfer of clinically relevant metastatic molecules. Journal of Experimental & Clinical Cancer Research, 37, 245. https://doi.org/10.1186/s13046-018-0915-z.

76. King, H. W., Michael, M. Z., & Gleadle, J. M. (2012). Hypoxic enhancement of exosome release by breast cancer cells. BMC Cancer, 12, 421. https://doi.org/10.1186/1471-2407-12-421.

77. Wang, T., Gilkes, D. M., Takano, N., Xiang, L., Luo, W., Bishop, C. J., Chaturvedi, P., Green, J. J., & Semenza, G. L. (2014). Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis. Proceedings of the National Academy of Sciences, 111, E3234–E3242. https://doi.org/10.1073/pnas.1410041111.

78. Shao, C., Yang, F., Miao, S., Liu, W., Wang, C., Shu, Y., & Shen, H. (2018). Role of hypoxia-induced exosomes in tumor biology. Molecular Cancer, 17, 120. https://doi.org/10.1186/s12943-018-0869-y.

79. Parolini, I., Federici, C., Raggi, C., Lugini, L., Palleschi, S., de Milito, A., Cossia, C., Jessi, E., Logozzi, M., Molinari, A., Colone, M., Tatti, M., Sargiacomo, M., & Fais, S. (2009). Microenvironmental pH is a key factor for exosome traffic in tumor cells. The Journal of Biological Chemistry, 284, 34211–34222. https://doi.org/10.1074/jbc.M109.041152.

80. Logozzi, M., Mizzoni, D., Angelini, D., et al. (2018). Microenvironmental pH and exosome levels interplay in human cancer cell lines of different histotypes. Cancers (Basel), 10, 370. https://doi.org/10.3390/cancers10100370.

81. Ratajczak, J., Wysockynskyi, M., Hayek, F., Janowska-Wieczorek, A., & Ratajczak, M. Z. (2006). Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia, 20, 1487–1495. https://doi.org/10.1038/sj.leu.2404296.

82. Federici, C., Petrucci, F., Caimi, S., Cesolini, A., Logozzi, M., Borghi, M., D’ilio, S., Lugini, L., Violante, N., Azzarito, T., Majorani, C., Brambilla, D., & Fais, S. (2014). Exosome release and low pH belong to a framework of resistance of human melanoma cells to cisplatin. PLoS One, 9, 1–11. https://doi.org/10.1371/journal.pone.0088193.

83. Ban, J.-J., Lee, M., Im, W., & Kim, M. (2015). Low pH increases the yield of exosome isolation. Biochemical and Biophysical Research Communications, 467, 342–345. https://doi.org/10.1016/j.bbrc.2015.04.127.
97. Lazar, I., Clement, E., Attane, C., Muller, C., & Nieto, L. (2018). Extracellular acidosis and hypoxia. The Journal of Biological Chemistry, 287, 17117–17127. https://doi.org/10.1074/jbc.M117.836782.

98. Recouvreux, M. V., & Commisso, C. (2017). Macropinocytosis: a mechanism of extracellular remodeling in cancer. Front. Oncol., 7, 1–17. https://doi.org/10.3389/fonc.2017.00216.

99. Vescovi, A., Piccolo, S., & Marini, J. C. (2014). Exosomes: extracellular vesicles that promote cell–cell communication in cancer. Cancer Metastasis Rev., 33, 101–112. https://doi.org/10.1007/s10555-013-9325-0.

100. García-Carpintero, Y., Martínez-Campos, J., & De La Torre, E. (2014). Exosome-mediated delivery of extracellular vesicles to tumor cells. Cancer Metastasis Rev., 33, 101–112. https://doi.org/10.1007/s10555-013-9325-0.

101. Sanjuán, J., Geffner Fernández-Calotti, J. R., Salamone, G., et al. (2014). Metastatic cells HMC class I-restricted presentation by adipocytes improves uptake of antigens and. Journal of Immigrant & Refugee Services, 17, 3196–3204. https://doi.org/10.1004/jimmunol.172.5.3196.

102. Park, S.-Y., Bae, D.-J., Kim, M.-J., Piao, M. L., & Kim, I. S. (2012). Extracellular low pH modulates phosphatidylinerine-dependent phagocytosis in macrophages by increasing stabilin-1 expression. The Journal of Biological Chemistry, 287, 11261–11271. https://doi.org/10.1074/jbc.M111.310953.

103. Zhao, H., Yang, L., Buddour, J., Aichraja, A., Bernard, V., Moss, T., Marini, J. C., Tudawe, T., Seviour, E. G., San Lucas, F. A., Alvarez, H., Gupta, S., Maiti, S. N., Cooper, L., Pieloh, D., Ram, P. T., Maitra, A., & Nagrath, D. (2016). Tumor microenvironment derived exosomes pletropically modulate cancer cell metabolism. Elife, 5, e10250. https://doi.org/10.7554/eLife.10250.

104. Sano, S., Ishimi, Y., Yamaguchi, T., Yamazaki, T., Tanaka, M., Shiota, M., Osada-Oka, M., Nakamura, Y., Wei, M., Wainbuchi, H., Iwao, H., & Yoshiyama, M. (2014). Lipid synthesis is promoted by hypoxic adipocyte-derived exosomes in 3T3-L1 cells. Biochemical and Biophysical Research Communications, 445, 327–333. https://doi.org/10.1016/j.bbrc.2014.01.183.

105. Peppicelli, S., Bianchini, F., Torre, E., & Calorini, L. (2014). Contribution of acidic melanoma cells undergoing epithelial-to-mesenchymal transition to aggressiveness of non-acidic melanoma cells. Clinical & Experimental Metastasis, 31, 423–433. https://doi.org/10.1007/s10585-014-9637-6.

106. Kucharzewska, P., Christianson, H. C., Welch, J. E., et al. (2013). Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proceedings of the National Academy of Sciences, 110, 7312–7317. https://doi.org/10.1073/pnas.1220998110.

107. Svensson, K. J., Kucharzewska, P., Christianson, H. C., Skold, S., Liljeqvist, T., Johansson, M. C., Mogelin, M., Bengzon, J., Ruf, W., & Belting, M. (2016). Hypoxia triggers a proangiogenic pathway involving cancer cell microvesicles and PAR-2-mediated heparin-binding EGF signaling in endothelial cells. Proceedings of the National Academy of Sciences, 113, 13147–13152. https://doi.org/10.1073/pnas.1104261110.

108. Sanderson, R. D., Bandari, S. K., & Vlodavsky, I. (2017). Proteases and glycosidases on the surface of exosomes: newly discovered mechanisms for extracellular remodeling. Matrix Biology, https://doi.org/10.1016/j.matbio.2017.10.007.

109. dos Anjos Pultz, B., Andrs Cordero da Luz, F., Socorro Faria, S., et al. (2017). The multifaceted role of extracellular vesicles in metastasis: priming the soil for seeding. International Journal of Cancer, 140, 2397–2407. https://doi.org/10.1002/ijc.30595.

110. Syn, N., Wang, L., Sethi, G., et al. (2016). Exosome-mediated metastasis from epithelial–mesenchymal transition to escape from immunosurveillance. Trends in Pharmaceutical Sciences, 37, 606–617. https://doi.org/10.1016/j.tips.2016.04.006.

111. Pimentel, H., Zhang, H., Matei, I. R., et al. (2017). Pre-metastatic niches: organ-specific homes for metastases. Nature Reviews. Cancer, 17, 302–317. https://doi.org/10.1038/nrc.2017.6.

112. Weiss, U. H., Birztele, F., Kollmorgen, G., & Kugler, R. (2017). The multiple roles of exosomes in metastasis. CANCER GENOMICS AND PROTEOMICS, 14, 1–16. https://doi.org/10.21873/cgp.20015.

113. Ramteke, A., Ting, H., Agarwal, C., et al. (2015). Exosomes secreted under hypoxia enhance invasiveness and stemness of prostate cancer cells by targeting adherens junction molecules. Molecular Carcinogenesis, 54, 554–565. https://doi.org/10.1002/mc.22124.
114. Erler, J. T., Bennewith, K. L., Cox, T. R., Lang, G., Bird, D., Koong, A., le, Q. T., & Giaccia, A. J. (2009). Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. *Cancer Cell, 15*, 35–44. https://doi.org/10.1016/j.ccr.2008.11.012.

115. de Jong, O. G., van Balkom, B. W. M., Gremmels, H., & Verhaar, M. C. (2016). Exosomes from hypoxic endothelial cells have increased collagen crosslinking activity through up-regulation of lysyl oxidase-like 2. *Journal of Cellular and Molecular Medicine, 20*, 342–350. https://doi.org/10.1111/jcmm.12730.

116. Elkin, S. R., Bendris, N., Reis, C. R., et al. (2015). A systematic analysis reveals heterogeneous changes in the endocytic activities of cancer cells. *Cancer Research, 75*, 4640–4650. https://doi.org/10.1158/0008-5472.CAN-15-0939.

117. Sliwkowski, M. X., & Mellman, I. (2013). Antibody therapeutics in cancer. *Science (80-)*, 341, 1192–1198. https://doi.org/10.1126/science.1241145.

118. Bourseau-Guilmain, E., Menard, J. A., Lindqvist, E., et al. (2016). Hypoxia regulates global membrane protein endocytosis through caveolin-1 in cancer cells. *Nature Communications, 7*, 11371. https://doi.org/10.1038/ncomms11371.

119. Robertson, N., Potter, C., & Harris, A. L. (2004). Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. *Cancer Research, 64*, 6160–6165. https://doi.org/10.1158/0008-5472.CAN-03-2224.

120. Supuran, C. T. (2008). Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. *Nature Reviews. Drug Discovery, 7*, 168–181. https://doi.org/10.1038/nrd2467.

121. Mboge, M., Mahon, B., McKenna, R., & Frost, S. (2018). Carbonic anhydrases: role in pH control and cancer. *Metabolites, 8*, 19. https://doi.org/10.3390/metabo810019.

122. Ivanov, S., Liao, S.-Y., Ivanova, A., Danilkovich-Miagkova, A., Tarasova, N., Weirich, G., Merrill, M. J., Proescholdt, M. A., Oldfield, E. H., Lee, J., Zavada, J., Waheed, A., Sly, W., Lerman, M. I., & Stanbridge, E. J. (2001). Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. *The American Journal of Pathology, 158*, 905–919. https://doi.org/10.1016/S0002-9440(10)64038-2.

123. Muselaers, C. H. J., Boers-Sonderen, M. J., van Oostenbrugge, T. J., Boerman, O. C., Desar, I. M. E., Stillebroer, A. B., Mulder, S. F., van Herpen, C. M. L., Langenhuijsen, J. F., Oosterwijk, E., Oyen, W. J. G., & Mulders, P. F. A. (2016). Phase 2 study of lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. *European Urology, 69*, 767–770. https://doi.org/10.1016/j.eururo.2015.11.033.

124. Christianson, H. C., Menard, J. A., Chandran, V. I., et al. (2017). Tumor antigen glycosaminoglycan modification regulates antibody-drug conjugate delivery and cytotoxicity. *Oncotarget, 8*, 66960–66974. https://doi.org/10.18632/oncotarget.16921.